An update on genomic-guided therapies for pediatric solid tumors

Pui Chi Tsui; Yin Fai Lee; Zoey Wing Yee Liu; Laura Ren Huey Ip; Wenying Piao; Alan Kwok Shing Chiang; Vivian Wai Yan Lui

doi:10.2217/fon-2017-0003

An update on genomic-guided therapies for pediatric solid tumors

Pui Chi Tsui, Yin Fai Lee, Zoey Wing Yee Liu, Laura Ren Huey Ip, Wenying Piao, Alan Kwok Shing Chiang, Vivian Wai Yan Lui

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Currently, out of the 82 US FDA-approved targeted therapies for adult cancer treatments, only three are approved for use in children irrespective of their genomic status. Apart from leukemia, only a handful of genomic-based trials involving children with solid tumors are ongoing. Emerging genomic data for pediatric solid tumors may facilitate the development of precision medicine in pediatric patients. Here, we provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data (from cBioPortal database, Pediatric Cancer Genome Project, Therapeutically Applicable Research to Generate Effective Treatments) and additional non-whole-exome sequencing studies. Potential druggable events are highlighted and discussed so as to facilitate preclinical and clinical research in this area.

Original language	English (US)
Pages (from-to)	1345-1358
Number of pages	14
Journal	Future Oncology
Volume	13
Issue number	15
DOIs	https://doi.org/10.2217/fon-2017-0003
State	Published - Jun 2017
Externally published	Yes

Keywords

clinical trials on targeted therapies
pediatric solid tumors
whole-exome sequencing

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2017-0003

Cite this

@article{854b3c75f5f34c81ae428bafb24f113f,

title = "An update on genomic-guided therapies for pediatric solid tumors",

abstract = "Currently, out of the 82 US FDA-approved targeted therapies for adult cancer treatments, only three are approved for use in children irrespective of their genomic status. Apart from leukemia, only a handful of genomic-based trials involving children with solid tumors are ongoing. Emerging genomic data for pediatric solid tumors may facilitate the development of precision medicine in pediatric patients. Here, we provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data (from cBioPortal database, Pediatric Cancer Genome Project, Therapeutically Applicable Research to Generate Effective Treatments) and additional non-whole-exome sequencing studies. Potential druggable events are highlighted and discussed so as to facilitate preclinical and clinical research in this area.",

keywords = "clinical trials on targeted therapies, pediatric solid tumors, whole-exome sequencing",

author = "Tsui, {Pui Chi} and Lee, {Yin Fai} and Liu, {Zoey Wing Yee} and Ip, {Laura Ren Huey} and Wenying Piao and Chiang, {Alan Kwok Shing} and Lui, {Vivian Wai Yan}",

note = "Funding Information: VWY Lui served as a scientific consultant for Novartis, Hong Kong. This study is supported by the Seed Grant of Strategic Research Theme for Cancer, The University of Hong Kong of AKSC. VWY Lui is funded by the Research Grant Council, Hong Kong (#17114814, #17121616, General Research Fund; T12-401/13-R, Theme-based Research Scheme), and the Start-up Fund, School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong. W Piao is funded by the Faculty Postdoctoral Fellowship Scheme, Faculty of Medicine, The Chinese University of Hong Kong. Publisher Copyright: {\textcopyright} 2017 Future Medicine Ltd.",

year = "2017",

month = jun,

doi = "10.2217/fon-2017-0003",

language = "English (US)",

volume = "13",

pages = "1345--1358",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "15",

}

TY - JOUR

T1 - An update on genomic-guided therapies for pediatric solid tumors

AU - Tsui, Pui Chi

AU - Lee, Yin Fai

AU - Liu, Zoey Wing Yee

AU - Ip, Laura Ren Huey

AU - Piao, Wenying

AU - Chiang, Alan Kwok Shing

AU - Lui, Vivian Wai Yan

N1 - Funding Information: VWY Lui served as a scientific consultant for Novartis, Hong Kong. This study is supported by the Seed Grant of Strategic Research Theme for Cancer, The University of Hong Kong of AKSC. VWY Lui is funded by the Research Grant Council, Hong Kong (#17114814, #17121616, General Research Fund; T12-401/13-R, Theme-based Research Scheme), and the Start-up Fund, School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong. W Piao is funded by the Faculty Postdoctoral Fellowship Scheme, Faculty of Medicine, The Chinese University of Hong Kong. Publisher Copyright: © 2017 Future Medicine Ltd.

PY - 2017/6

Y1 - 2017/6

N2 - Currently, out of the 82 US FDA-approved targeted therapies for adult cancer treatments, only three are approved for use in children irrespective of their genomic status. Apart from leukemia, only a handful of genomic-based trials involving children with solid tumors are ongoing. Emerging genomic data for pediatric solid tumors may facilitate the development of precision medicine in pediatric patients. Here, we provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data (from cBioPortal database, Pediatric Cancer Genome Project, Therapeutically Applicable Research to Generate Effective Treatments) and additional non-whole-exome sequencing studies. Potential druggable events are highlighted and discussed so as to facilitate preclinical and clinical research in this area.

AB - Currently, out of the 82 US FDA-approved targeted therapies for adult cancer treatments, only three are approved for use in children irrespective of their genomic status. Apart from leukemia, only a handful of genomic-based trials involving children with solid tumors are ongoing. Emerging genomic data for pediatric solid tumors may facilitate the development of precision medicine in pediatric patients. Here, we provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data (from cBioPortal database, Pediatric Cancer Genome Project, Therapeutically Applicable Research to Generate Effective Treatments) and additional non-whole-exome sequencing studies. Potential druggable events are highlighted and discussed so as to facilitate preclinical and clinical research in this area.

KW - clinical trials on targeted therapies

KW - pediatric solid tumors

KW - whole-exome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85021401346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021401346&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0003

DO - 10.2217/fon-2017-0003

M3 - Review article

C2 - 28589766

AN - SCOPUS:85021401346

SN - 1479-6694

VL - 13

SP - 1345

EP - 1358

JO - Future Oncology

JF - Future Oncology

IS - 15

ER -

An update on genomic-guided therapies for pediatric solid tumors

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this